References
1. Bunte K, Beikler T. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases. Int J Mol Sci 2019; 20: pii: E3394.
2.Horváth R, Rožková D, Lašťovička J, Poloučková A, Sedláček P, Sedivá A, Spíšek R. Expansion of T helper type 17 lymphocytes in patients with chronic granulomatous disease. Clin Exp Immunol 2011; 166:26-33.
3. Villegas JA, Van Wassenhove J, Le Panse R, Berrih-Aknin S, Dragin N. An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients. Ann N Y Acad Sci 2018; 413:154-162.
4. Ghoreschi K, Laurence A, Yang XP, Hirahara K, O’Shea JJ. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 2011; 32:395-401.
5. Barbi J, Pardoll D, Pan F. Treg functional stability and its responsiveness to the microenvironment. Immunol Rev 2014; 259:115-139.
6. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, et al. TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function. Nature 2008; 453: 236-240.
7. Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, Nakaya M, Takaesu G, Hori S, et al. Foxp3 inhibits RORgammat-mediated IL mRNA transcription through direct interaction with RORgammat. J Biol Chem 2008; 283: 17003-17008.
8. Nistala K, Wedderburn LR. Th17 and regulatory T cells: Rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology (Oxford) 2009; 48: 602–606.
9. Nyirenda MH, Morandi E, Vinkemeier U, Constantin-Teodosiu D, Drinkwater S, Mee M, King L, Podda G, et al. TLR2 Stimulation Regulates the Balance between Regulatory T Cell and Th17 Function: A Novel Mechanism of Reduced Regulatory T Cell Function in Multiple Sclerosis. J Immunol 2015; 194: 5761-5774
10. Yang BH, Hagemann S, Mamareli P, Lauer U, Hoffmann U, Beckstette M, Föhse L, et al. Prinz I Foxp3+ T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation. Mucosal Immunol 2015; 9:444-457.
11. Huang H, Lu Z, Jiang C, Liu J, Wang Y, Xu Z. Imbalance between th17 and regulatory t-cells in sarcoidosis. Int J Mol Sci 2013; 14: 21463-21473.
12. Masuda M, Matsumoto M, Tanaka S, Nakajima K, Yamada N, Ido N, Ohtsuka T, Nishida M, et al. Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. Journal of Neuroimmunology 2010; 225: 123-131.
13. Roche JC, Capablo JL, Larrad L, Gervas-Arruga J, Ara JR, Sanchez A, Alarcia R. Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve 2011; 44:278e80.
14. Alahgholi-Hajibehzad M, Kasapoglu P, Jafari R, Rezaei N. The role of T regulatory cells in immunopathogenesis of myasthenia gravis: implications for therapeutics. Expert Rev Clin Immunol 2015; 11:859-870.
15. Wang Z, Wang W, Chen Y, Wei D. T helper type 17 cells expand in patients with myasthenia-associated thymoma. Scand J Immunol 2012; 76:54-61.
16. Liu YM, Zhang H, Zhang P, Meng F, Chen Y, Wang Y, Yao Y, Qi B. Autoimmune regulator expression in thymomas with or without autoimmune disease. Immunol Lett 2014; 161:50-56.
17. Wang GJ, Wang YG, Zhang P, Chen Y, Liu Y, Guo F, Zhang H. Establishment and characterization of a novel cell line derived from thymoma with myasthenia gravis patients. Thoracic Cancer 2015; 6: 194-201.
18. Yasuda K, Takeuchi Y, Hirota K. The pathogenicity of Th17 cells in autoimmune diseases. Semin Immunopathol 2019; 41:283-297.
19. Klein L, Robey EA, Hsieh CS. Central CD4+ T cell tolerance: deletion versus regulatory T cell differentiation. Nat Rev Immunol 2019; 19:7-18.
20. Villegas JA, Bayer AC, Ider K, Bismuth J, Truffault F, Roussin R, Santelmo N, Le Panse R, et al. IL-23/Th17 cell pathway: A promising target to alleviate thymic inflammation maintenance in myasthenia gravis. J Autoimmun 2019; 98:59-73
21. Hosseini M, Robat-Jazi B, Shaygannejad V, Naffisi S, Mirmossayeb O, Rezaei A, Mansourian M, Esmaeil N. Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis. Neuroimmunomodulation 2017; 24:264-270.
22. Scarpino S, Di Napoli A, Stoppacciaro A, Antonelli M, Pilozzi E, Chiarle R, Palestro G, Marino M, et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 2007; 149:504-512.
23. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8:967-974.
24. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40:1830-1835.
25. Dardalhon V. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 2008; 31: 252-256.
26. Bettelli E. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441: 235-238.
27. Souroujon MC, Aricha R, Feferman T, Mizrachi K, Reuveni D, Fuchs S. Regulatory T cell-based immunotherapies in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci 2012; 1274:120-126.